Innoviva, Inc. (INVA)
Upgrades & Downgrades
Latest INVA news
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
13 July 2022
Theravance Biopharma, Inc. (NASDAQ: TBPH) has agreed to sell all of its units in Theravance Respiratory Company, LLC, representing 85% economic interest in the sales-based royalty rights on worldwide ...
La Jolla Pharmaceutical (LJPC) Stock Skyrockets on Innoviva Acquisition News
11 July 2022
A headline-grabbing takeover deal could be impactful for the medical community - and today, it's definitely huge news for LJPC stock holders. The post La Jolla Pharmaceutical (LJPC) Stock Skyrockets o...
Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal
11 July 2022
Innoviva Inc (NASDAQ: INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average ...
Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share
23 May 2022
Innoviva Inc (NASDAQ: INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of E...
Earnings Preview: Innoviva (INVA) Q1 Earnings Expected to Decline
20 April 2022
Innoviva (INVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bet on These 4 Low-Beta Stocks to Combat Market Volatility
6 April 2022
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), OP Bancorp (OPBK) and United Fire Group (UFCS) are well poised to gain.
Is Innoviva (INVA) Outperforming Other Medical Stocks This Year?
1 April 2022
Here is how Innoviva (INVA) and McKesson (MCK) have performed compared to their sector so far this year.
1 Healthcare Stock That Could Fly Higher After a Strong Q4
5 March 2022
This pharmaceutical company is growing revenue and profits from drugs it doesn't market or sell.
Sail Through the Choppy Market With These 4 Low-Beta Stocks
4 March 2022
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Meridian (VIVO), Innoviva (INVA), Horace (HMN) and Maravai LifeSciences (MRVI) are well poised to gain.